TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23857975

Group type: EXPERIMENTAL
Intervention: Chemotherapy before radiation (CT1) - three cycles of cisplatin and etoposide before radiation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Chemotherapy after radiation (RT1) - same chemotherapy regimen after radiation
Number of subjects: 112
Study: 21793694

Group type: EXPERIMENTAL
Intervention: Wingate test at 17:00
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wingate test at 07:00
Number of subjects: 22
Study: 19341156

Group type: EXPERIMENTAL
Intervention: Rolling Store intervention with nutrition education program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 40
Study: 16522905

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched cereal bars (50 mg/d)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo cereal bars
Number of subjects: 117
Study: 12507748

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11109512

Group type: EXPERIMENTAL
Intervention: felodipine (10 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg)
Number of subjects: 40
Study: 9144764

Group type: EXPERIMENTAL
Intervention: Media-school interventions
Number of subjects: 2860

Group type: COMPARATOR
Intervention: School interventions only
Number of subjects: 2860
Study: 7964942

Group type: EXPERIMENTAL
Intervention: Hepatic arterial floxuridine (FUDR) 0.30 mg/kg/d, leucovorin (LV) 15 mg/m2/d, dexamethasone (Dec) 20 mg total dose as a 14-day hepatic arterial infusion via an implantable pump alternating with 2 weeks of saline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Previous trial of hepatic arterial FUDR and LV without Dec
Number of subjects: 62
Study: 2891368

Group type: EXPERIMENTAL
Intervention: Temelastine 75 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temelastine and Terfenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31764108

Group type: EXPERIMENTAL
Intervention: HIV testing offered to adults with symptoms; 1424 referred for testing (37% of symptomatic adults), 1065 accepted testing (75% of those referred).
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Testing in health facilities.
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Testing in mobile units.
Number of subjects: 3818

Group type: EXPERIMENTAL
Intervention: Reporting 4-5 symptoms.
Number of subjects: 3818
Study: 29051160

Group type: EXPERIMENTAL
Intervention: Diabetes + no microvascular complication
Number of subjects: 3385

Group type: EXPERIMENTAL
Intervention: Diabetes + microvascular complications
Number of subjects: 3385

Group type: EXPERIMENTAL
Intervention: Diabetes + no microvascular complication (prior hospitalization for heart failure)
Number of subjects: 3385

Group type: EXPERIMENTAL
Intervention: Diabetes + microvascular complications (prior hospitalization for heart failure)
Number of subjects: 3385
Study: 26615179

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20mg/day)
Number of subjects: 10576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10576
Study: 24554791

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (60-min class twice a week for 16 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 21427067

Group type: EXPERIMENTAL
Intervention: Venlafaxine 50 mg 1 hour prior to oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 18803639

Group type: EXPERIMENTAL
Intervention: Extended NO analysis
Number of subjects: 89
Study: 17470165

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil as needed
Number of subjects: 180

Group type: COMPARATOR
Intervention: 20 mg paroxetine daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Squeeze technique daily
Number of subjects: 180
Study: 15316983

Group type: EXPERIMENTAL
Intervention: Creatine treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 11067391

Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 0
Study: 9061895

Group type: EXPERIMENTAL
Intervention: Familiar voices in a gender judgment task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-modal repetition priming with short SOA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Familiar voices and faces
Number of subjects: 0
Study: 1327082

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0
Study: 4072874

Group type: EXPERIMENTAL
Intervention: Quiniday, 1200 mg once daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Quinidine sulfate (Quinora, 300 mg four times daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Quinidine sulfate (Quinidex Extentabs, 600 mg twice daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Quinidine gluconate (Quinaglute Dura‐Tabs, 648 mg twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All quinidine preparations
Number of subjects: 76
Study: 2942207

Group type: EXPERIMENTAL
Intervention: Routine care plus a maximally informative booklet (experimental group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine care plus a minimally informative booklet (placebo group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 63
Study: 29880162

Group type: EXPERIMENTAL
Intervention: 16 mg Dexamethasone IV drip
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16 mg Dexamethasone subcutaneous injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (500 cc saline infusion)
Number of subjects: 120
Study: 28654721

Group type: EXPERIMENTAL
Intervention: Resin infiltration with increased infiltration time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin infiltration alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of resin infiltration and bleaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 0
Study: 25862762

Group type: EXPERIMENTAL
Intervention: HDF4
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HD8
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HDF8
Number of subjects: 13
Study: 23096708

Group type: EXPERIMENTAL
Intervention: EGCG (Epigallocatechin-3-gallate)
Number of subjects: 0
Study: 21918160

Group type: EXPERIMENTAL
Intervention: 30° head-up position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study: 18465244

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. (RAC group, n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus moxifloxacine 400 mg o.d. and amoxicillin 1,000 mg b.d. (RAM group, n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus moxifloxacine 400 mg o.d. (EAM group, n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus clarithromycin 500 mg b.d. (EAC group, n = 30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: EAM group
Number of subjects: 120
Study: 16546738

Group type: EXPERIMENTAL
Intervention: Oral theophylline at daily dose of 4 to 6 mg/kg for 16 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group without medication other than beta2 antagonist
Number of subjects: 56
Study: 12606523

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10848858

Group type: EXPERIMENTAL
Intervention: Green-hub needle (21 G)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Blue-hub needle (23 G)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Blue-hub needle (23 G) with local anaesthetic
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Green-hub needle (21 G) with local anaesthetic
Number of subjects: 98
Study: 9313387

Group type: EXPERIMENTAL
Intervention: Padded, short forearm orthosis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Two elastic orthoses
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Longer forearm length orthosis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All three commercial wrist orthoses
Number of subjects: 42
Study: 8228078

Group type: EXPERIMENTAL
Intervention: 1/10(4) adrenaline
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Adrenaline plus 1% polidocanol
Number of subjects: 63
Study: 3514074

Group type: EXPERIMENTAL
Intervention: Small-field, wedged, inhomogeneous 3-week X-ray treatment followed by two radical radium insertions delivering 80% of a radical intracavity dose
Number of subjects: 296

Group type: COMPARATOR
Intervention: 4-week homogeneous, large-field X-ray technique supplemented by a single intracavitary insertion giving 50% of a radical intracavitary dose
Number of subjects: 296
Study: 29559720

Group type: EXPERIMENTAL
Intervention: 67% sucrose/33% fructose (67%S:33%F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50% sucrose/50% fructose (50%S:50%F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 33% sucrose/67% fructose (33%S:67%F)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% sucrose
Number of subjects: 12
Study: 27618389

Group type: EXPERIMENTAL
Intervention: Massage according to the 5-5-5 rule (5 times per day for 5 minutes for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No massage post-treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (massage and no massage)
Number of subjects: 20
Study: 24287976

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel applied to surgical site in 6 patients.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no PRP gel applied) with 5 patients.
Number of subjects: 11
Study: 22540912

Group type: COMPARATOR
Intervention: Metformin alone (1000 mg twice daily)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Metformin plus rosiglitazone (4 mg twice a day)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Metformin plus lifestyle intervention
Number of subjects: 699
Study: 19709100

Group type: EXPERIMENTAL
Intervention: Polyphenon E ointment 10% (G(10%))
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Polyphenon E ointment 15% (G(15%))
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Vehicle (G(Veh))
Number of subjects: 1005
Study: 18802906

Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) with papillary muscle realignment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) only
Number of subjects: 30
Study: 17240929

Group type: EXPERIMENTAL
Intervention: Whitening paint-on gel with polyethylene strip barrier
Number of subjects: 33

Group type: COMPARATOR
Intervention: Whitening paint-on gel alone
Number of subjects: 33
Study: 12419855

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10987605

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BV pacing)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both pacing periods
Number of subjects: 32
Study: 8970662

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 32
Study: 1333719

Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine (0.4 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 micrograms/kg)
Number of subjects: 38
Study: 3881263

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/day (Trental 400 t.d.s.)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Acetylsalicylic acid and dipyridamole (ASAD, 1,050 mg + 150 mg/day)
Number of subjects: 138
Study: 30531477

Group type: EXPERIMENTAL
Intervention: PF-06372865 2.5 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PF-06372865 7.5 mg twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28270181

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel-epirubicin (PE) regimen
Number of subjects: 293

Group type: COMPARATOR
Intervention: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen
Number of subjects: 293
Study: 27498527

Group type: EXPERIMENTAL
Intervention: Lower limb peripheral nerve blocks with sedation or general anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 24901546

Group type: EXPERIMENTAL
Intervention: Single-slice analysis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole kidney analysis
Number of subjects: 22
Study: 23111035

Group type: COMPARATOR
Intervention: Laparoscopic simulator (n = 11)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: XBOX 360 gaming console (n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nintendo DS handheld gaming system (n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Video game play (more than 10 hours weekly)
Number of subjects: 31
Study: 19730966

Group type: EXPERIMENTAL
Intervention: Combination of granisetron 0.1 mg iv and promethazine 6.25 mg iv
Number of subjects: 100

Group type: COMPARATOR
Intervention: Promethazine 6.25 mg iv
Number of subjects: 100

Group type: COMPARATOR
Intervention: Granisetron 0.1 mg iv
Number of subjects: 100
Study: 17972482

Group type: EXPERIMENTAL
Intervention: Presenting distracting visual transients repeatedly prior to the change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional filtering of distracting transient signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of presenting transient signals
Number of subjects: 0
Study: 15023195

Group type: EXPERIMENTAL
Intervention: Nutrition Intervention (NI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study: 11760633

Group type: EXPERIMENTAL
Intervention: 2 day training seminar for nurse case managers
Number of subjects: 65
Study: 9591489

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) gonadotropins
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) gonadotropins
Number of subjects: 71
Study: 7873701

Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to female slides
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to male and female slides
Number of subjects: 6

Group type: COMPARATOR
Intervention: Contingent negative variation (CNV) to adult female slides
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Contingent negative variation (CNV) to female adults and female children
Number of subjects: 6
Study: 3348141

Group type: EXPERIMENTAL
Intervention: 120 mg of sustained-release isosorbide dinitrate (ISDN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60 mg of sustained-release nifedipine
Number of subjects: 40
Study: 31135099

Group type: EXPERIMENTAL
Intervention: Miliacin encapsulated within polar lipids (MePL)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30017873

Group type: EXPERIMENTAL
Intervention: Standardized dry ivy leaf extract syrup along with regular nasal irrigation for five days after nasal packing removal
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nasal lavage only
Number of subjects: 70
Study: 28223381

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study: 25750540

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study: 24316325

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) at intervention sites
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) at observational sites
Number of subjects: 201
Study: 22637938

Group type: EXPERIMENTAL
Intervention: Institutional rearing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Community control
Number of subjects: 114
Study: 19572082

Group type: EXPERIMENTAL
Intervention: Complete compression ultrasound (CCUS)
Number of subjects: 3871

Group type: EXPERIMENTAL
Intervention: Withholding anticoagulant therapy after negative CCUS
Number of subjects: 3871
Study: 17631801

Group type: EXPERIMENTAL
Intervention: High-dose Dinggui Oil (DGO-H, 1.2 g, 3 times daily)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low-dose Dinggui Oil (DGO-L, 0.8 g, 3 times daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (5.0 g, 3 times daily)
Number of subjects: 198
Study: 14996420

Group type: EXPERIMENTAL
Intervention: Paternal lymphocyte (PL) immunotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Autologous lymphocyte (AL) immunotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Third party lymphocyte (TPL) immunotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal saline (NS) control
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-treated (NT) control group
Number of subjects: 124
Study: 11575618

Group type: EXPERIMENTAL
Intervention: Caution to be realistic
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard malingering indexes (Infrequency, F; Back Side, F, Fb; F-Correction, F-K; and Infrequency-Psychopathology, F(p))
Number of subjects: 124
Study: 9703284

Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 60

Group type: COMPARATOR
Intervention: IL‐2 with IFN‐alpha
Number of subjects: 60
Study: 9410372

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone) 90 mg per day
Number of subjects: 283

Group type: COMPARATOR
Intervention: Oral progesterone (Utrogestan) 300 mg per day
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Oral progesterone (Utrogestan)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Safety parameters for both groups
Number of subjects: 283
Study: 2333843

Group type: EXPERIMENTAL
Intervention: Low-phylloquinone diet (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postoperative fasting (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard diet (n = 7)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-phylloquinone diet after 3 days (n = 8)
Number of subjects: 22
Study: 6785626

Group type: EXPERIMENTAL
Intervention: Test preparation with lysozyme, papain and bacitracin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparative preparation with a disinfectant only
Number of subjects: 100
Study: 31557351

Group type: EXPERIMENTAL
Intervention: T1D Exchange Registry
Number of subjects: 51524

Group type: COMPARATOR
Intervention: DPV Registry
Number of subjects: 51524

Group type: EXPERIMENTAL
Intervention: T1D Exchange Registry (injection users)
Number of subjects: 51524

Group type: COMPARATOR
Intervention: DPV Registry (injection users)
Number of subjects: 51524

Group type: EXPERIMENTAL
Intervention: Both Registries (minority status)
Number of subjects: 51524
Study: 31156048

Group type: EXPERIMENTAL
Intervention: Intensity Gradient (IG)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Average Acceleration (AvAcc)
Number of subjects: 145
Study: 28049170

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 µg twice daily) for 6 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 µg twice daily) for 30 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (500/50 µg twice daily) for 30 months
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 26482071

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 25863853

Group type: EXPERIMENTAL
Intervention: Glaucoma group (31 patients using at least 1 topical IOP-lowering medication)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (30 patients with no diagnosis of glaucoma or history of topical therapy usage)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Glaucoma group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 23419875

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 90
Study: 21485550

Group type: EXPERIMENTAL
Intervention: Nanometer silver dressing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaseline dressing
Number of subjects: 60
Study: 18616708

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 17053357

Group type: EXPERIMENTAL
Intervention: Perpetration of physical or sexual violence against female partners
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Severe perpetration of violence (both physical and sexual)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Overall perpetration of intimate partner violence
Number of subjects: 1275
Study: 12611785

Group type: EXPERIMENTAL
Intervention: Cognitive therapy in addition to antidepressants and clinical management
Number of subjects: 158

Group type: COMPARATOR
Intervention: Antidepressants and clinical management alone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 158
Study: 11004617

Group type: EXPERIMENTAL
Intervention: Ifetroban
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 9821994

Group type: EXPERIMENTAL
Intervention: Fast-track cardiac anesthetic regimen
Number of subjects: 617